DELFI Diagnostics
delfidiagnostics.com
Actively hiring
Diagnostic Tests & IVD
Precision Medicine
As featured in
View 1 job
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Total raised
$331.6M
5 rounds on record
Latest round
$225M
Venture round · Jun 2022 · 4 yr ago
Team
120
US Form 5500 (plan participants) · Dec 2025 · -17% in a year
Hiring now
5
+2 posted in 30 days
Backers
4
Foresite Capital, Illumina Ventures
The money's age
Long since its last round
51 months since the last round · and hiring
Momentum
16/100
hiring for its size
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 27
Board appointment DELFI Diagnostics Appoints Charles Newton to Board of Directors · PRNewswire
Dec 1, 2025
Took on debt financing $34.3M · SEC Form D
Oct 29, 2024
New executive DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening · PRNewswire
Aug 26, 2024
New executive DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer · PRNewswire
Jun 11, 2024
Partnership Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities · PRNewswire
Oct 10, 2023
Launched DELFI Diagnostics introduces FirstLook Lung blood test · Medical Device Network
Jun 10, 2022
Raised a round Venture round $225M · SEC Form D
Jan 12, 2021
Raised a round Venture round $101.1M · SEC Form D
Aug 12, 2019
Raised a round Venture round $5.5M · SEC Form D
2019
Founded
Jun 18, 2018
Raised a round Venture round $15k · SEC Form D
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Dec 2025 | $34.3M | — | SEC Form D |
| Venture round | Jun 2022 | $225M | — | SEC Form D |
| Venture round | Jan 2021 | $101.1M | — | SEC Form D |
| Venture round | Aug 2019 | $5.5M | — | SEC Form D |
| Venture round | Jun 2018 | $15k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Delfi Diagnostics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Nicholas DracopoliExecutive OfficerSEC Form D
Victor VelculescuDirectorSEC Form D
William StevensExecutive OfficerSEC Form D
Peter BachExecutive OfficerSEC Form D
Jennifer BuechelExecutive OfficerSEC Form D
Douglas SchenkelExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Foresite Capital 
Menlo Ventures 
OrbiMed Similar startupsby what they do, their industry and backers
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and…
BreathEasy analyses your breath profile, helping your doctor understand your cancer risk. 90.8% sensitivity and 91.3% specificity in a…
Engineering a futurewithout cancer deaths.. Rapid at-homediagnostics.
Hemex Health develops point-of-care blood diagnostics that help healthcare providers diagnose, monitor, and manage chronic diseases…
Company Focus Our mission is to pioneer early lung cancer detection and save lives. Lung cancer is the second most common cancer worldwide…
Skip to the content About Reveal-Dx is a Seattle-based software company whose vision is to dramatically improve lung cancer outcomes. We do…
News
Blood Test Boosts Lung Cancer Screening Participation
Clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with CT screening.
Read more
Report
DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the lung cancer bood test available in all 50 states.
Read more
Report
Delfi Diagnostics Gains NY State Approval for Blood-Based Lung Cancer LDT
Delfi's laboratory-developed lung cancer screening test is now available nationwide while the company continues to pursue FDA approval.
Read more
Report
DELFI Diagnostics Receives New York State Department of Health Clinical Laboratory Permit, Completing Authorization to Serve Health Systems Across All 50 States
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory...
Read more
Report
The New Blood Test That's Helping Doctors Screen For Lung Cancer Sooner
Learn how doctors at Hackensack Meridian Health are using a new lung cancer blood test to screen for the disease sooner and improve cancer outcomes.
Read more
Report
Delfi Diagnostics Gives 'First Look' at Clinical Utility of cfDNA Assay in Lung Cancer Screening
Access to the liquid biopsy nearly tripled lung cancer screening rates in a demonstration of the test's clinical utility.
Read more
Report
DELFI Diagnostics to Present First Clinical Utility Data for Blood-Based Lung Cancer Screening at ATS 2026 International Conference
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and...
Read more
Report
DELFI Diagnostics Appoints Charles Newton to Board of Directors
/PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative AI-powered blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer...
Read more
Report
Johns Hopkins Researchers Develop Fragmentomic Test for Pancreatic Cancer Treatment Response
The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.
Read more
Report
Could a blood test detect lung cancer?
Lung cancer accounts for 1 in 5 cancer-related deaths in the United States. While doctors say lung cancer is often treatable if caught early, millions of Americans who should be getting screened for the disease each year are not either due to lack of awar
Read more
Report
Show more news
Tech stack
Technologies named in job postings at DELFI Diagnostics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
10
Postings analysed
2
Stack modernity
83/100
Languages
Python
C#
C++
Java
Rust
Frameworks & libraries
NumPy
Cloud & platforms
AWS
Developer tools
Git
Practices & domains
CI/CD
Machine Learning
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$155k
Typical range
$110k – $175k
Open positions
5
5
Jobs
Middle
20%
Senior
80%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $146k | $146k |
| Senior | 4 | $163k | $110k – $175k |
Highest paying role
Accounting Operations Manager
$175k
Normalized to USD per year
People
Nicholas Dracopoli
Executive Officer
Victor Velculescu
Director
William Stevens
Executive Officer
Peter Bach
Executive Officer
Jennifer Buechel
Executive Officer
Douglas Schenkel
Executive Officer
Lee-Ann Smith-Freeman
Executive Officer
Susan Tousi
Executive Officer, Director
Amoolya Singh
Executive Officer
Greg Yap
Director
Elizabeth Homans
Director
Rishi Gupta
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
66/100
Growing
Open positions
5
2 opened / 2 closed in 30 days
Median time-to-fill
83 days
faster than 19% of the market
ATS activity
Every ~10 hours
09/30/2026
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
40% ▼
Data Science
20% ▲
Finance
20% ▲
Industrial Engineering
20% ▲
Activity Timeline
Added Machine Learning to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
1
Countries
1
Busiest office
Palo Alto
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Palo Alto
United States
HQ
For the latest press releases and media coverage, visit:
5 open roles 5 posted in 90 days 40% engineering 50-200 est. staff $151k Avg Salary
hires for Industrial Engineering, Data Science, Finance
Page
United States
HQ
Company Information and Fact Page
1810 Embarcadero Road, Suite 100, Palo Alto, CA 94303
Medina
United States
Regional office
Other Applications
Medina, J.E., et al. "Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers." Cancer Discovery. 2024. DOI:
Jobs
$130k – $170k per year • Hybrid • Full-Time • 5+ years exp • Master's Degree • Palo Alto
Python
NumPy
Machine Learning
Apply
Financials
Total raised
$365.9M
Latest round
Debt Financing
Funding rounds
5